Extended-Release and Long-Acting Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS)

Jointly sponsored by Global Education Group and Rockpointe. This educational activity is supported by an independent educational grant from the Extended-Release/Long-Acting Opioid Analgesic REMS Program Companies. Please see http://ce.er-laopioidrems.com.

This activity is certified for credit.

Tuesday, September 4

Start Time

End Time

Gracia 7
Level 3

Program Description

Pain is a significant public health problem, affecting more than 100 million adults in the US. The use of narcotic medications for pain management has increased dramatically in the US over the past two decades. However, pain patients are often undertreated due to a variety of physician- and patient-related concerns and barriers.

Despite the pain-relieving properties of opioid medications, the potential for misuse, abuse, addiction, and overdose causes many providers apprehension in prescribing, The Food and Drug Administration (FDA) developed the Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits outweigh the risks for the use of long-acting and extended-release opioid analgesics.

Extended-Release and Long-Acting Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS), incorporates the REMS blueprint into education that is designed to induce changes in knowledge, competence, and performance that will translate into improved quality of patient care and reduced pain for patients.

Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Describe how to counsel patients and caregivers on safe use of ER/LA opioid analgesics, including proper storage and disposal
  • Review how to safely initiate therapy, modify dose, and discontinue use of ER/LA opioid analgesics
  • Explain general and product-specific drug information concerning ER/LA opioid analgesics
  • Identify patients who are candidates for treatment with ER/LA opioid analgesics
  • Describe how to minimize risks of opioid abuse, addiction, and diversion while managing patients who are receiving ongoing therapy with ER/LA opioid analgesic

Bill McCarberg, MD
Lynn Webster, MD

Contact Name
Paula Larson

Contact Phone
(908) 962-6478

Contact email


Related Content